Fortitude Biomedicines is a biopharmaceutical company developing the next generation of antibody-based biotherapeutics to treat autoimmune diseases and cancer. The team pursues precision cell targeting and antibody-drug conjugates (ADCs) using proprietary GLUE-DAC technology to achieve potent efficacy with improved safety. Located in North America (Waltham, Massachusetts), the company combines cutting-edge biology with strategic partnerships to advance disease-modifying therapies and bring innovative treatments to patients.